Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Long-Term Debt Repayments (2016 - 2018)

Amicus Therapeutics (FOLD) has disclosed Long-Term Debt Repayments for 8 consecutive years, with -$218000.0 as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Long-Term Debt Repayments fell 327.08% year-over-year to -$218000.0, compared with a TTM value of -$218000.0 through Dec 2021, down 53.52%, and an annual FY2023 reading of $408.0 million, changed N/A over the prior year.
  • Long-Term Debt Repayments was -$218000.0 for Q4 2018 at Amicus Therapeutics, down from $76000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $5.6 million in Q1 2014 and bottomed at -$218000.0 in Q4 2018.
  • Average Long-Term Debt Repayments over 4 years is $549181.8, with a median of $71000.0 recorded in 2016.
  • The sharpest move saw Long-Term Debt Repayments increased 28.0% in 2017, then tumbled 327.08% in 2018.
  • Year by year, Long-Term Debt Repayments stood at $5.6 million in 2014, then tumbled by 98.66% to $75000.0 in 2016, then rose by 28.0% to $96000.0 in 2017, then tumbled by 327.08% to -$218000.0 in 2018.
  • Business Quant data shows Long-Term Debt Repayments for FOLD at -$218000.0 in Q4 2018, $76000.0 in Q3 2018, and $71000.0 in Q2 2018.